<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366330">
  <stage>Registered</stage>
  <submitdate>13/05/2014</submitdate>
  <approvaldate>20/05/2014</approvaldate>
  <actrnumber>ACTRN12614000533695</actrnumber>
  <trial_identification>
    <studytitle>Effects of infant formula enriched with butyrate on immune and intestinal functions </studytitle>
    <scientifictitle>administration of a formula enriched with butyrate in healthy newborns to assess an improvement in intestinal and immune functions </scientifictitle>
    <utrn>U1111-1156-8042</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>prevention of immunological impairment in healty newborns</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>administation of a standard infant formula enriched with butyrate (30ml/L) given in sachets of 10 mg, administered three times a day for the first 28 days of life. In the first days of life we directly monitor the adherence to the intervention. Then we contact mothers </interventions>
    <comparator>administration of a standard formula not enriched with probiotics and prebiotics</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> Development of innate immunity by measurement of beta-defensins, cathelecidin LL-37 in faecal and blood samples and development of adaptive immunity through the measurement of sIgA in  faecal and blood samples</outcome>
      <timepoint>at the third and fifth day of life and at the twenty-eighth day of life</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Development of functional maturation of  intestine through the monitoring of the citrulline levels in blood samples.</outcome>
      <timepoint>at twenty-eight days of life</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>assessment of clinical improvement through evacuative patter,  episodes of colic and crying, regurgitation, vomiting. These outcomes is assessed by daily diary completed by infant's mother.</outcome>
      <timepoint>at the third and fifth day of life and at the twenty-eighth day of life</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Caucasian newborns exclusively fed artificially for maternal choice, gestational age greater than 37 weeks . Obtaining informed consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Maternal factors: a history of autoimmune diseases, cancers, infectious or inflammatory diseases that required antibiotic therapy in pregnancy, diabetes, preeclampsia, lipid disorders, vaginal swab positive for Group B streptococcus, prolonged rupture of membranes.
Neonatal Factors: twins, a history of severe asphyxia, meconium aspiration syndrome, immunodeficiencies, congenital infections, genetic disorders and chromosomal abnormalities, malformations.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>randomization list, Random allocation Software, version 1.0, 2004</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>variables are analyzed by chi squared test. The Spearman correlation test is used to demonstrate the correlation between two continuous variable.  Continuous variables are analyzed and expressed as means and standard deviations by ANOVA test. The software for statistical analysis and graphical representation of the results is SPSS for Windows, ver 14, StatsDirect, SamplePower, GraphPad. the number of participants needed to achieve study objectives was determined considering we wish to obtain a difference of at least 15% in the concentrations of antimicrobial peptides between the two groups under consideration (power 87%, p &lt;0.05 alpha error 0.05) and considering a drop out of 20%</statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>4/06/2012</anticipatedstartdate>
    <actualstartdate>4/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/12/2012</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>"Federico II" University of Naples</primarysponsorname>
    <primarysponsoraddress>via  s. pansini, 5 
80131 Naples</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>"Federico II" University of Naples</fundingname>
      <fundingaddress>via s. pansini, 5 
80131 Naples</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the efficacy of a new infant formula containing butyrate, in stimulating the development of neonatal immune system and in improving intestinal immune responses.  </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Annalisa Passariello</name>
      <address>"Federico II" University of Naples
Via S. Pansini, 5
80131  Naples</address>
      <phone> +39 081 7462680</phone>
      <fax>+39 081 5451278</fax>
      <email>annalisa.passariello@unina.it</email>
      <country>Italy</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Annalisa Passariello</name>
      <address>"Federico II" University of Naples
Via S. Pansini, 5
80131 Naples</address>
      <phone> +39 081 7462680</phone>
      <fax>+39 081 5451278</fax>
      <email>annalisa.passariello@unina.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Annalisa Passariello </name>
      <address>"Federico II" University of Naples
Via S. Pansini, 5 
80131 Naples</address>
      <phone> +39 081 7462680</phone>
      <fax>+39 081 5451278</fax>
      <email>annalisa.passariello@unina.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Annalisa Passariello</name>
      <address>via S. Pansini, 5
80131  Naples</address>
      <phone>0817462680</phone>
      <fax>0817462680</fax>
      <email>annalisa.passariello@unina.it</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>